Testing a blood marker to predict pancreatic cancer outcomes
Treatments studied
Part of Cancer clinical trials.
This study looks at a test called RPSA to see if it can help predict how pancreatic cancer may turn out. It includes people being treated at Reims University Hospital for pancreatic tumors that can be removed (or may become removable).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are being treated at Reims University Hospital for a pancreatic tumor that is resectable or possibly resectable
- You may have chemotherapy before surgery (neoadjuvant) or not
- A doctor has confirmed pancreatic cancer (PDAC) as the diagnosis
- You must sign the informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if a simple blood test can find tiny bits of cancer DNA after your pancreatic surgery, which may help detect if cancer comes back earlier than scans. By joining, you'll help doctors learn how to better monitor the disease and guide future treatments.
This study looks at blood and stool samples from people with advanced pancreatic cancer to understand how their body's metabolism and gut bacteria affect their disease and treatment. It aims to find better ways to predict and improve treatment outcomes.
This study uses a special blood test to look for tiny amounts of cancer DNA after your pancreatic cancer surgery. It may help doctors see early if the cancer is coming back, so they can act sooner.
This study looks at “biomarkers” (test signals in tissue or blood) in people with pancreatic cancer. It may help researchers understand the disease better and find ways to predict or track it.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
This study looks at DNA signals from blood tests (so-called “ctDNA” and another type of DNA test) in people with early-stage pancreatic cancer. It aims to see whether these tests can help track cancer after surgery and check for signs of return.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.